Biological Research
Sequence to structure insights into Lassa virus population-level biophysical properties and glycoprotein structure catalogue
This research analyzes Lassa virus (LASV) protein properties at a population scale, focusing on the glycoprotein (GP) which is crucial for humoral immunity. It reveals lineage-specific biophysical patterns, including protein length variation driven by short indels, and subtle differences in amino-acid composition. Notably, lineage III glycoproteins are consistently heavier than lineage II, driven by shifts towards heavier residues at specific sites. Computational structural modeling and flow-cytometric assays confirm the N-terminal GP1 indel is structurally and functionally tolerated. These findings provide a catalogue of GP structures vital for vaccine and therapeutic design against LASV.
Executive Impact & Key Findings
This study leverages population-scale analysis and computational modeling to uncover critical biophysical patterns in Lassa virus, providing foundational insights for targeted therapeutic and vaccine development.
180 Da
Daltons heavier (Lineage III GP)
95.1%
Accuracy in lineage classification
613
LASV GPC sequences modeled
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
LASV proteins exhibit significant lineage-specific differences in molecular mass and length, with GP and Z proteins showing the most variation. Lineage III consistently encodes heavier proteins on the S segment than lineage II.
| Protein | Lineage | Length Range (aa) | Mean Mass (Da) | Mean Mass Δ from IV (Da) |
|---|---|---|---|---|
| GPC | II | 490-491 | 55,711.53 | 113.51 |
| GPC | III | 490 | 55,891.90 | -66.86 |
| NP | II | 569 | 62,806.78 | 121.70 |
| NP | III | 569 | 62,952.35 | -23.87 |
The N-terminal indel around GPC residues 60/61 drives lineage-specific length polymorphism, particularly between 490-aa and 491-aa forms. This indel is structurally tolerated and does not significantly perturb GPC expression or antibody recognition.
Enterprise Process Flow
Identify N-terminal indel (GPC 60/61)
→
Observe 490/491-aa length polymorphism
→
Lineage-specific occurrence (e.g., Lineage II has 490-aa form, Lineage IV/V has 491-aa form)
→
Model GPC structures with and without indel
→
Validate structural tolerance via flow cytometry
→
Conclude indel is functionally tolerated
Lineage III GPC is approximately 180 Da heavier than Lineage II GPC, primarily due to shifts towards heavier amino acids (e.g., Arginine, Glutamine) at specific lineage-informative positions, rather than a single dominant substitution.
180 Da
heavier on average for Lineage III GPC compared to Lineage II, driven by specific amino acid shifts.
Advanced ROI Calculator
Estimate the potential return on investment for implementing AI solutions based on our research. Adjust the parameters to see your projected savings and efficiency gains.
Estimated Annual Savings
Annual Hours Reclaimed
Implementation Roadmap
Our strategic phased approach ensures seamless integration and maximum impact of AI solutions, from initial variant identification to automated therapeutic design.
AI-Driven Variant Identification
Utilize AI to rapidly identify and characterize novel LASV protein variants and indels across emerging lineages, providing early warning for potential shifts in pathogenicity or immunogenicity. This ensures proactive surveillance and rapid response capabilities for public health agencies.
Predictive Biophysical Modeling
Deploy advanced computational biophysical modeling to predict the structural and functional consequences of observed sequence variations. This allows for in-silico screening of potential vaccine candidates or therapeutic targets, reducing experimental lead times and costs.
Automated Vaccine/Therapeutic Design
Integrate population-scale structural catalogues into AI-driven platforms for accelerated design of multi-lineage vaccines and antiviral therapies. This ensures broad protection against diverse LASV strains and adapts to emerging variants, overcoming current limitations in drug development.
Ready to Transform Your Research?
Book a personalized consultation to explore how our Enterprise AI solutions can accelerate your R&D, improve public health surveillance, and deliver measurable impact.
Ready to Get Started?
Book Your Free Consultation.
Let's Discuss Your AI Strategy!
Lets Discuss Your Needs
Select a Date
Sun
Mon
Tue
Wed
Thu
Fri
Sat